ID: ALA4643471

Max Phase: Preclinical

Molecular Formula: C20H23FN2O2

Molecular Weight: 342.41

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C[C@H](NC1CCCc2cc(OCc3ccccc3F)ccc21)C(N)=O

Standard InChI:  InChI=1S/C20H23FN2O2/c1-13(20(22)24)23-19-8-4-6-14-11-16(9-10-17(14)19)25-12-15-5-2-3-7-18(15)21/h2-3,5,7,9-11,13,19,23H,4,6,8,12H2,1H3,(H2,22,24)/t13-,19?/m0/s1

Standard InChI Key:  DLNNBDXKXPONQD-YTJLLHSVSA-N

Associated Targets(Human)

Sodium channel protein type III alpha subunit 275 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HERG 29587 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 342.41Molecular Weight (Monoisotopic): 342.1744AlogP: 3.25#Rotatable Bonds: 6
Polar Surface Area: 64.35Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 8.17CX LogP: 3.47CX LogD: 2.64
Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.85Np Likeness Score: -0.95

References

1. Witty DR, Alvaro G, Derjean D, Giblin GMP, Gunn K, Large C, Macpherson DT, Morisset V, Owen D, Palmer J, Rugiero F, Tate S, Hinckley CA, Naik H..  (2020)  Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.,  11  (9): [PMID:32945812] [10.1021/acsmedchemlett.0c00263]

Source